Medication adherence is often treated as a patient-level issue, but its consequences extend far beyond an individual missed dose. For providers, poor adherence can mean preventable deterioration, avoidable utilization, and limited visibility into whether a treatment plan is working. For sponsors, it can compromise trial data, reduce statistical power, delay timelines, and introduce uncertainty into high-stakes development decisions.
In the United States, medication nonadherence is associated with an estimated $100 billion to $300 billion in annual direct healthcare costs. It is also linked to more hospital admissions, poorer outcomes, and higher morbidity and mortality. In clinical research, the financial impact can be equally consequential: when participants do not take investigational products as directed, sponsors may need to recruit more participants, extend follow-up, or repeat studies to preserve the evidence needed for a regulatory decision.
The core issue is not simply whether a dose was missed. It is whether organizations can distinguish treatment failure from nonadherence early enough to respond. As care and research become increasingly decentralized, that distinction is becoming essential to both clinical quality and operational efficiency.
The problem
Poor medication adherence takes many forms. A patient may never begin therapy, take doses inconsistently, use the wrong dose or timing, stop treatment early, or report adherence that does not reflect actual dosing behavior. Each scenario can create clinical and operational consequences, particularly when providers or research teams have limited visibility between visits.
For providers, a lack of reliable adherence information can lead to an incomplete picture of treatment response. A clinician may interpret persistent symptoms, abnormal laboratory values, or lack of improvement as evidence that a therapy is ineffective. That can prompt unnecessary dose escalation, medication switching, additional diagnostics, or avoidable referrals—when the central issue may be that treatment was not taken as prescribed.
The impact also reaches care delivery economics. Nonadherence is associated with higher rates of hospitalization and suboptimal health outcomes, placing additional demand on clinicians, care coordinators, and health systems. In value-based and risk-bearing care models, avoidable utilization can directly affect performance and reimbursement while increasing pressure on already constrained teams.
For sponsors, nonadherence can dilute apparent treatment effects and make a promising therapy look less effective than it is. When investigational-product exposure is uncertain, the relationship between dose, safety, efficacy, and outcomes becomes harder to interpret. This may introduce variability into endpoint data, reduce statistical power, and require additional participants to compensate for missing or unreliable exposure data.
The operational implications are substantial. One published modeling analysis estimated that a Phase III trial facing 40% investigational-product nonadherence would need to enroll an additional 460 participants to maintain equivalent statistical power, at an estimated $12 million in added enrollment cost. In the same analysis, reducing nonadherence by one percentage point was associated with 13 fewer participants required and an estimated $336,000 in savings. While actual impact varies by protocol, disease area, and trial design, the broader lesson is clear: adherence risk is a material driver of cost, timeline uncertainty, and evidence quality.
Industry perspective
Medication adherence is increasingly viewed as a data-quality and performance issue, not solely as a matter of patient motivation. This reframing matters because conventional adherence measures—self-report, pill counts, pharmacy refill information, or periodic site conversations—can be incomplete or retrospective. They may identify a problem only after a patient’s outcome, safety profile, or study data has already been affected.
In clinical care, providers are managing more chronic disease through remote, hybrid, and ambulatory models. Digital communication, remote monitoring, and patient-support programs can expand access, but they also make it harder to rely on in-person observation. As a result, care organizations need practical methods to identify disengagement earlier, understand which patients require intervention, and target staff time where it can have the greatest impact.
Clinical research faces a related challenge. Sponsors have invested heavily in decentralized and hybrid trial capabilities to reduce participation burden, improve access, and potentially speed recruitment. Yet remote participation does not eliminate the need for reliable evidence of treatment exposure. In fact, as fewer activities occur at a research site, the ability to monitor and support protocol adherence can become even more important.
Research and regulatory discussions increasingly recognize that poor adherence may distort a trial’s results. The EMERGE guideline notes that suboptimal adherence affects study quality and can add significant costs; it also highlights the possibility that a compound can fail to reach approval because nonadherence obscures its true effect. The financial stakes are high: the same guideline cites an estimate from the Tufts Center for the Study of Drug Development that the average cost of bringing a drug to approval was $2.6 billion, making avoidable trial inefficiency particularly consequential.
Technology has an expanding role in addressing this problem, but it should not be viewed as a substitute for human support. Effective adherence programs combine patient-centered design with timely data, clear communication, and workflows that enable action. A reminder alone may help a patient remember. Verified dosing information, however, can help a provider or study team understand whether additional outreach, education, safety assessment, or protocol support is warranted.
AICure’s perspective
AICure approaches medication adherence as a measurable behavior that can be supported, verified, and translated into actionable insight. The company’s H.Code platform uses AI-powered computer vision, predictive analytics, and smartphone-based patient interaction to help sponsors, CROs, and providers observe and assist medication and clinical-behavior adherence remotely.
At the center of this approach is the difference between a reported dose and a verified dosing event. In a clinical trial or care setting, self-report may indicate that a patient took medication, but it does not always clarify whether the dose was taken by the intended person, at the intended time, or in accordance with the prescribed workflow. AICure’s technology has been designed to use a patient’s mobile device to identify the patient, identify the medication, and confirm ingestion through computer-vision-based analysis, with date and time records associated with individual doses.
That level of visibility can support earlier intervention. Rather than waiting for a missed study visit, an unexpected clinical result, or a patient disclosure at a follow-up appointment, a care or research team can use adherence data to identify emerging patterns. For example, repeated late doses, declining engagement, or a sequence of missed doses may indicate that a patient needs assistance before nonadherence becomes persistent.
For sponsors, the potential value is improved confidence in treatment-exposure data. Reliable visibility into dosing behavior can help teams contextualize efficacy and safety results, assess protocol risks, and focus site or patient-support resources on participants who need them most. It may also reduce the need to compensate for nonadherence through unnecessary enrollment expansion or prolonged study timelines.
For providers, the objective is more personalized and efficient support. When adherence concerns are surfaced earlier, teams can direct outreach toward practical barriers such as adverse effects, cost concerns, confusion about instructions, routine disruptions, or reduced motivation. The technology should make it easier to have the right clinical conversation—not replace it.
Key takeaways
Poor medication adherence is expensive because it creates uncertainty. Providers may spend time responding to apparent treatment failure without knowing whether medication exposure was adequate. Sponsors may face diluted treatment effects, higher enrollment needs, delayed timelines, and evidence gaps that weaken confidence in development decisions.
The financial burden is considerable. Medication nonadherence is associated with an estimated $100 billion to $300 billion in annual U.S. healthcare costs, while clinical-trial nonadherence can increase the participant numbers and operational investment needed to preserve statistical power.cdc+1
Organizations can take a more proactive approach by treating adherence as a measurable, manageable risk. That includes designing protocols and treatment plans that reduce burden, offering timely patient support, identifying behavioral patterns early, and using data that is sufficiently reliable to guide intervention.
AICure’s perspective is that verified adherence data can help transform medication-taking from an unobserved assumption into an actionable signal. When sponsors and providers can distinguish nonadherence from genuine nonresponse earlier, they are better positioned to protect patients, preserve data quality, and make more efficient decisions across the healthcare lifecycle.